Understanding of leukemic stem cells and their clinical implications

Molecular Cancer

Review

Xuefei Wang¹  Ji-Long Chen²  Shile Huang³ 

[1] CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, 100101, Beijing, China;University of Chinese Academy of Sciences, Beijing, China;CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, 100101, Beijing, China;University of Chinese Academy of Sciences, Beijing, China;College of Animal Sciences, Fujian Agriculture and Forestry University, Fuzhou, China;Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, LA, USA;

关键词: Cancer stem cell;    Leukemia;    Leukemic stem cell;    Surface markers;    BM niche;    ncRNAs;    Clinical implications;   

DOI  :  10.1186/s12943-016-0574-7

 received in 2016-10-02, accepted in 2016-12-19,  发布年份 2017

来源: Springer

【 摘 要 】

Since leukemic stem cells (LSCs) or cancer stem cells (CSCs) were found in acute myeloid leukemia (AML) in 1997, extensive studies have been contributed to identification and characterization of such cell populations in various tissues. LSCs are now generally recognized as a heterogeneous cell population that possesses the capacities of self-renewal, proliferation and differentiation. It has been shown that LSCs are regulated by critical surface antigens, microenvironment, intrinsic signaling pathways, and novel molecules such as some ncRNAs. To date, significant progress has been made in understanding of LSCs, leading to the development of numerous LSCs-targeted therapies. Moreover, various novel therapeutic agents targeting LSCs are undergoing clinical trials. Here, we review current knowledge of LSCs, and discuss the potential therapies and their challenges that are being tested in clinical trials for evaluation of their effects on leukemias.

【 授权许可】

CC BY   
© The Author(s). 2017